Efficacy of Dorzagliatin and Related Factors in a Real‐World Cohort of Type 2 Diabetes

Background: This study is aimed at evaluating the efficacy of dorzagliatin and identify factors associated with better glucose control in a cohort of patients with T2D in a real‐world setting. Methods: This is a single‐center cohort study conducted in a real‐world setting. Patients with T2D who had newly initiated dorzagliatin were enrolled in the study. The follow‐up period ranged from at least 3 to up to 9 months, during which FBG, PBG, HbA1c, lipid profile, renal function, and MA/UCREA were measured and recorded every 3 months. Results: The study cohort of patients with T2D had a mean age of 64.0 years, a diabetes duration of 17.9 years, an average of 4 antidiabetic drugs, and an HbA1c of 7.55%. FBG decreased by 0.60 mmol/L ( p = 0.026), 2hPBG reduced by 2.15 mmol/L ( p < 0.001), and HbA1c declined by 0.30% ( p < 0.001) after treatment with dorzagliatin. Renal function significantly improved following dorzagliatin intervention (eGFR, estimated treatment difference 4.20 mL/kg/1.73m 2 , 74.5 vs. 78.7 mL/kg/1.73m 2 , p < 0.001). A regression model ( B = 0.556, Exp = 1.744, p = 0.006) suggested that BMI, baseline HbA1c, and duration of diabetes were independently associated with the treatment effectiveness of dorzagliatin (BMI, B = −0.191, p = 0.009; baseline HbA1c, B = 1.060, p < 0.001; and duration of diabetes, B = −0.058, p = 0.034). Conclusions: Dorzagliatin is effective in lowering glucose levels in patients with T2D in a real‐world setting. Patients with lower BMI, higher baseline HbA1c, and shorter duration of disease may be robust responders to dorzagliatin treatment.